Pulmonary Fibrosis News and Research

RSS

U.S. Senators introduce Pulmonary Fibrosis Research Enhancement Act

The Coalition for Pulmonary Fibrosis (CPF) announced today the Pulmonary Fibrosis Research Enhancement Act has been introduced in the Senate by Senators Chris Coons and Mike Crapo in the U.S. House of Representatives by Rep. Erik Paulsen and Rep. Tammy Baldwin.

13 Jul 2011

AJMS summarizes developments related to idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a common and severe lung disease of unknown cause and with no proven therapies. But researchers are pushing forward in investigating new clues to the development and effective treatment of IPF, according to a special symposium presented in The American Journal of the Medical Sciences (AJMS), official journal of the Southern Society for Clinical Investigation (SSCI).

8 Jul 2011

Enrollment commences in InterMune's Esbriet Phase 3 study for IPF

InterMune today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis.

8 Jul 2011

Study confirms link between delayed access to tertiary care for IPF, higher risk of death

Idiopathic pulmonary fibrosis (IPF)―scarring and thickening of the lungs from unknown causes―is the predominant condition leading to lung transplantation nationwide. Columbia University Medical Center researchers confirmed that delayed access to a tertiary care center for IPF is associated with a higher risk of death.

2 Jul 2011

Flamel, Digna Biotech enter joint development agreement for multiple products

Flamel Technologies SA and Digna Biotech SL today announced that the two companies have entered into a joint development agreement for the pre-clinical and clinical development of multiple products.

27 Jun 2011

Galectin-3 research uncovers new use for Modified Citrus Pectin in cardiovascular, heart disease

In a new important research study out of the UK, scientists found that the specific form of Modified Citrus Pectin developed by Isaac Eliaz, M.D. interrupts deadly kidney fibrosis by binding to galectin-3 molecules, decreasing the effects of inflammation and fibrosis in acute kidney injury.

24 May 2011

Scientists mimic dyskeratosis congenita through study of undifferentiated iPS cells

A rare genetic disease called dyskeratosis congenita, caused by the rapid shortening of telomeres, can be mimicked through the study of undifferentiated induced pluripotent stem cells, according to new findings from the Stanford University School of Medicine.

24 May 2011

Positive pirfenidone data in idiopathic pulmonary fibrosis to be presented at ATS conference

InterMune, Inc. today announced that an oral presentation and a poster presentation related to the company's development program for pirfenidone in idiopathic pulmonary fibrosis will be presented at the 2011 International Conference of the American Thoracic Society, being held in Denver May 13-18, 2011.

16 May 2011

The Lancet publishes two pirfenidone Phase 3 trial results in idiopathic pulmonary fibrosis

InterMune, Inc. today announced the publication of results from two Phase 3 trials demonstrating that treatment with pirfenidone, a novel antifibrotic and anti-inflammatory drug, was associated with favorable effects on lung function, 6-minute walk test distance and progression-free survival (PFS) in patients with mild to moderate idiopathic pulmonary fibrosis (IPF).

16 May 2011

Amira to present AM152 preclinical data in fibrotic disease at ATS Annual Meeting

Amira Pharmaceuticals, Inc. announced today that it will present preclinical data on AM152, an LPA1 receptor antagonist, during the Annual Meeting of the American Thoracic Society in Denver, Colorado.

12 May 2011

Promedior's PRM-151 clinical data in idiopathic pulmonary fibrosis to be presented at ATS 2011

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, today announced that data from a clinical study of PRM-151 will be presented at the 2011 American Thoracic Society International Conference, being held May 13-18, 2011 in Denver, CO.

5 May 2011

New genetic discovery in Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis and the Pulmonary Fibrosis Foundation applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis.

25 Apr 2011

Genetic variation associated with MUC5B gene may increase risk of developing Pulmonary Fibrosis

A new discovery in a deadly lung disease may change the direction of research while uncovering increased risk for many patients and families. The Coalition for Pulmonary Fibrosis (CPF) and the Pulmonary Fibrosis Foundation (PFF) applaud the efforts of scientists that led to the discovery of a genetic variation associated with the MUC5B gene which may increase the risk of developing Pulmonary Fibrosis (PF).

21 Apr 2011

New study finds no significant benefit of bosentan against IPF

A new study has demonstrated no significant benefit of taking the drug bosentan for idiopathic pulmonary fibrosis.

11 Apr 2011

La Jolla acquires GliaMed's novel class of compounds

La Jolla Pharmaceutical Company today announced that it has acquired the rights to a novel class of compounds known as Regenerative Immunophilin Ligands from privately held GliaMed, Inc.

5 Apr 2011

MicroRNAs may play a key role in future medicine

Since their discovery in the 1990s, microRNAs have proven to play a complex role in normal and abnormal functioning of many organ systems. In the April issue of Translational Research, entitled "MicroRNAs: A Potential New Frontier for Medicine," an international group of medical experts explores several themes related to our current understanding of microRNAs and the role they may play in the future of medicine.

24 Mar 2011

CPF applauds new guidelines for treatment of idiopathic pulmonary fibrosis

The Coalition for Pulmonary Fibrosis (CPF) applauds the joint statement issued by the American Thoracic Society for the first evidence-based clinical guidelines for the treatment of idiopathic pulmonary fibrosis (IPF). The guidelines represent progress in understanding of the disease and a milestone for patients. The devastating and deadly disease also called simply "Pulmonary Fibrosis" or "PF" has no FDA approved treatment and no cure.

18 Mar 2011

EC grants marketing authorization for InterMune's Esbriet to treat IPF

InterMune, Inc. today announced that the European Commission has granted marketing authorization for Esbriet. Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis, a progressive and fatal lung disease.

3 Mar 2011

Acute viral infection does not appear to cause exacerbation of IPF

Acute viral infection does not appear to be a primary cause of acute exacerbation of idiopathic pulmonary fibrosis, a progressive, deadly disease resulting in thickening and scarring of the lungs, according to a study conducted by researchers from the U.S., Korea and Japan.

28 Feb 2011

Single donor gifts lungs for two lung transplants

The University of Michigan Transplant Center celebrated a milestone recently, performing its 500th lung transplant. But there's much more to this story than a number.

17 Feb 2011